Table 1. Baseline clinicopathological and treatment characteristics of non-small-cell lung cancer patients receiving standard and extended pembrolizumab dosing during the COVID-19 pandemic.

	Standard dosing group (N = 72): n (%)	Extended dosing group (N = 18): n (%)	p-value
Sex   Male   Female	19 (26) 53 (74)	11 (61) 7 (39)	0.01†
ECOG   0   1   2 and above	4 (6) 64 (88) 4 (6)	0 (0) 18 (100) 0 (0)	0.56
Smoking status   Former   Current	52 (72) 20 (28)	13 (72) 5 (28)	1.00
Stage   IV	72 (100)	18 (100)	NA
Baseline bone metastasis   Presence   Absence	21 (29) 51 (71)	5 (28) 13 (72)	0.91
Baseline brain metastasis   Presence   Absence	18 (25) 54 (75)	2 (11) 16 (89)	0.34
Baseline adrenal metastasis   Presence   Absence	8 (11) 64 (89)	3 (17) 15 (83)	0.69
Baseline liver metastasis   Presence   Absence	9 (12.5) 63 (87.5)	1 (6) 17 (94)	0.68
Histology type   Squamous   Nonsquamous   Other‡	19 (26) 48 (67) 5 (7)	6 (33) 12 (67) 0 (0)	0.52
Reason for treatment discontinuation   Immunotoxicity   Progression   Completed treatment   Medical condition   Death	10 (14) 26 (36) 2 (2.5) 5 (7) 22 (30.5)	5 (28) 1 (5) 5 (28) 0 (0) 0 (0)	<0.01†
Still on treatment	7 (10)	7 (39)	<0.01†
Number of treatment cycles, median	3.5	19§	<0.01†
Alive at 6 months (n = 54; 60%)	37 (51)	17 (94)	<0.001†
Alive at 12 months (n = 41; 46%)	24 (33)	17 (94)	<0.001†
Alive at data cutoff (n = 36; 40%)	19 (26)	17 (94)	<0.001†

^†Statistically significant.

^‡Other histologies included poorly differentiated carcinoma with or without spindle cells.

^§On average, 11.5 cycles received on 3-weekly dosing before switch to 6-weekly dosing.

ECOG: Eastern Cooperative Oncology Group; NA: Not applicable.